Perspectives on the mGluR2/3 agonists as a therapeutic target for schizophrenia: Still promising or a dead end?

Perspectives on the mGluR2/3 agonists as a therapeutic target for schizophrenia: Still promising or a dead end?
复制标题

mGluR2/3 激动剂作为精神分裂症治疗靶点的观点:仍然有希望还是死胡同?

DOI:
10.1016/j.pnpbp.2015.02.012
复制
发表时间:
2015-07-03
影响因子:
5.6
通讯作者:
Gao, Wen-Jun
Gao, Wen-Jun
中科院分区:
医学2区
文献类型:
--
作者:
Li, Meng-Lin;Hu, Xi-Quan;Li, Feng;Gao, Wen-Jun

文献摘要

参考文献

被引文献

相似文献

Group II metabotropic glutamate receptor (mGluR2/3) agonists once showed promise as non-dopaminergic antipsychotic drugs because of their efficacy in alleviating symptoms of schizophrenia (SZ) in both animal models and human patients. However, the recent failure of Phase III clinical trials dealt a huge blow to the scientific community and the aftershock of the setback in mGluR2/3 research can be felt everywhere from grant support and laboratory studies to paper publication. An immediate question raised is whether mGluR2/3 is still a promising therapeutic target for schizophrenia. Answering this question is not easy, but apparently a new strategy is needed. This article provides a focused review of literature on the study of mGluR2/3 agonists, especially on mGluR2/3 agonists’ mechanism of action and efficacy in both normal conditions and animal models of SZ, as well as clinical studies in human patients with the disease. We argue that the cellular and molecular actions of mGluR2/3 agonists, the distinct roles between mGluR2 and mGluR3, as well as their effects on different stages of the disease and different subpopulations of patients, remain incompletely studied. Until the mechanisms associated with mGluR2/3 are clearly elucidated and all treatment options are tested, it would be a great mistake to terminate the study of mGluR2/3 as a therapeutic target for schizophrenia. This review will thus shed light on the comprehensive features of the translational potential mGluR2/3 agonists as well as the need for further research into the more selective activation of mGluR2.
DOI: 10.1021/jm1012165
发表时间: 2011-01-13
影响因子: 7.3
作者:
Dhanya RP;Sidique S;Sheffler DJ;Nickols HH;Herath A;Yang L;Dahl R;Ardecky R;Semenova S;Markou A;Conn PJ;Cosford ND
通讯作者: Cosford ND
DOI: 10.1097/jcp.0b013e3182542633
发表时间: 2012-06-01
影响因子: 2.9
作者:
Ayan-Oshodi, Mosun;Wondmagegnehu, Eshetu T.;Kinon, Bruce J.
通讯作者: Kinon, Bruce J.
DOI: 10.1007/s002130050072
发表时间: 2000-03-01
期刊: PSYCHOPHARMACOLOGY
影响因子: 3.4
作者:
Cartmell, J;Monn, JA;Schoepp, DD
通讯作者: Schoepp, DD
DOI: 10.1113/jphysiol.2013.255075
发表时间: 2013-08-15
影响因子: 5.5
作者:
Cheng, Jia;Liu, Wenhua;Yan, Zhen
通讯作者: Yan, Zhen
DOI: 10.1016/j.tips.2008.10.006
发表时间: 2009-01
影响因子: 13.8
作者:
Conn PJ;Lindsley CW;Jones CK
通讯作者: Jones CK